BiotechTube
ILIAD Biotechnologies

ILIAD Biotechnologies

San Diego, United States· Est.
iliadbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $127.2M

Overview

ILIAD Biotechnologies is a private, pre-revenue company advancing a differentiated vaccine platform targeting pertussis (whooping cough). Its core asset, BPZE1, is a live attenuated intranasal vaccine designed to induce mucosal, cellular, and humoral immunity, potentially offering superior and longer-lasting protection compared to current acellular vaccines. With two completed Phase 2 trials, the company is positioned to advance into later-stage development to address a clear unmet medical need in a large global market. ILIAD's strategy focuses on preventing disease in vulnerable populations, particularly infants, and potentially reducing bacterial carriage and transmission.

Infectious Disease

Technology Platform

Live attenuated, genetically modified Bordetella pertussis strain (BPZE1) delivered as a single-dose intranasal spray. Designed to induce mucosal, cellular, and humoral immunity to prevent disease and bacterial colonization/transmission.

Funding History

3
Total raised:$127.2M
Venture$115M
Series A$12M
Grant$200K

Opportunities

BPZE1 addresses the significant limitations of current acellular pertussis vaccines, namely waning immunity and failure to prevent bacterial transmission.
Its intranasal, single-dose regimen offers a potential improvement in convenience and efficacy, targeting a multi-billion dollar global vaccine market.
Successful development could position it as a best-in-class solution for both infant priming and adolescent/adult booster vaccinations.

Risk Factors

As a single-asset, pre-revenue company, ILIAD faces high clinical development risk in costly Phase 3 trials and regulatory risk for a novel live bacterial vaccine.
Market adoption is challenging, requiring displacement of entrenched vaccines and new recommendations from public health bodies.
The company is dependent on raising significant capital, leading to potential dilution or the need for a partnership.

Competitive Landscape

ILIAD competes in the pertussis vaccine market dominated by large players like GSK and Sanofi, who market acellular (aP) vaccines. Competition includes other next-generation candidates in development, such as novel antigen formulations, maternal vaccines, and other live attenuated strains. BPZE1's primary differentiation is its potential to block colonization and transmission, a feature current aP vaccines lack.

More companies in Biologics / Biosimilars →More companies in United States →